Skip to content
Zerit(stavudine)
Zerit (stavudine) is a small molecule pharmaceutical. Stavudine was first approved as Zerit on 1994-06-24. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Stavudine
Tradename
Company
Number
Date
Products
ZERITBristol Myers SquibbN-020412 DISCN1994-06-24
5 products, RLD
ZERITBristol Myers SquibbN-020413 DISCN1996-09-06
1 products, RLD
ZERIT XRBristol Myers SquibbN-021453 DISCN2002-12-31
4 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
stavudineANDA2019-01-16
zeritNew Drug Application2010-08-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Stavudine, Zerit Xr, Bristol Myers Squibb
71354652023-02-18DPU-167
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF04: Stavudine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR07: Stavudine, lamivudine and nevirapine
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ScabiesD012532B86——21—3
Lice infestationsD010373B85.2——11—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PediculusD01037422———4
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSTAVUDINE
INNstavudine
Description
Stavudine is a nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase It has a role as an antimetabolite, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral agent. It is an organic molecular entity, a nucleoside analogue and a dihydrofuran. It is functionally related to a thymine.
Classification
Small molecule
Drug classantineoplastics; antivirals (zidovudine group) (exception: edoxudine)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Identifiers
PDB—
CAS-ID3056-17-5
RxCUI59763
ChEMBL IDCHEMBL991
ChEBI ID63581
PubChem CID18283
DrugBankDB00649
UNII IDBO9LE4QFZF (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,290 documents
View more details
Safety
Black-box Warning
Black-box warning for: Stavudine, Zerit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
22 adverse events reported
View more details